Medicare Part D price negotiation update

Description

The Inflation Reduction Act and the resulting Medicare Part D price negotiations are shaping up to be the most far reaching of any event impacting pharma manufacturing in recent history.

Although the first set of negotiated prices for selected drugs will not take effect until January 1, 2026, the immediate impact has been fast and furious — more than a dozen lawsuits have been filed by pharmaceutical companies, advocacy groups and the US Chamber of Commerce. Industry media is ablaze with discussions on how price negotiations will impact the pricing of non-selected same-class drugs and biosimilars, as well as future drug development in general.

With the first-round negotiated prices for selected drugs to be made public on September 1, 2024, companies are preparing themselves for the second round of selections. This timely webinar will provide an update on:

• To-date information on the legal actions, existing price negotiations, and market reactions

• Drugs likely to be selected for the second round and their same-class competitors who will be impacted

• The changes and impact of out-of-pocket costs on enrollees

• Price negotiation benchmarking on selected drugs compared to net pricing on competitors

• How manufacturers should prepare for the overall impact to the industry

• Part D plan utilization management

Register for this webinar today to understand the profound impact of the Inflation Reduction Act and Medicare Part D price negotiations on the pharmaceutical industry.

Speakers: Mark McCoy, RPh, MBA - Director, Client Engagement Pricing Market Access and Reimbursement, ICON; Amith Shetty, PharmD, RPh - Senior Clinical & Market Access Specialist, ICON; Dr. Xin Zhao - Principal, Global Market Access, ICON.

Who Should Attend?

This webinar will benefit pharmaceutical and biotech professionals in the following areas:

• Market access/Marketing/Managed markets/Market research

• Real world evidence

• Regulatory affairs

• Channel marketing

• Clinical research

• Competitive intelligence

• Government affairs

• Health economics and outcomes research

What You Will Learn

Attendees will learn about:

• The ongoing legal challenges initiated by pharmaceutical companies and other stakeholders against the Inflation Reduction Act’s price negotiation provisions

• Drugs likely to be targeted in the upcoming rounds of Medicare Part D price negotiations

• The impact of changes to enrollees and drug manufacturers around reductions in patient out-of-pocket costs

• The future impact on Part D plan utilization management